GLG News by Physicians who Treat Insomnia (US)

The notion that Lilly is promulgating here by marketing Cialis as a daily preparation is that you can have it both ways, namely always being prepared for sexual relations that are spontaneous.  From an observer of the human comedy (me), this will sell very well as the Baby Boom ages.  No mention...

Allosteric modulation of the metabotropic glutamate receptor 5 (mGluR5) for treatment of schizophrenia seems highly promising from a basic science perspective.  It has not been well tested in the clinic yet.  The fact that two major pharmaceutical firms are now in the hunt towards clinical...

An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...

Lu AA21004 is a new "bis-aryl-sulphanyl modulator" that has both preclinical and clinical support for future development for market as an "affective modulator". (I use the term affective modulator because I doubt whether the ultimate indication for this agent will be based on anxiety or depression.) ...

Helping regenerate or preventing death of dopaminergic neurons in the motor system is novel and exciting.  That is the strategy described in the accomapanying clinical trial of insertion of a nerve growth factor gene into the putamen of patients with Parkinson’s disease—a region of the brain affected...

Here we go again; look at all metabolites of a successful drug for efficacy to increase your bang for the corporate buck.  Brilliant--because success is virtually assured at relatively little cost.  Venlafaxine is a reasonably good antidepressant, and in my experience, useful except in...

At this stage there is a paucity of antidepressants that are approved in adolescent depression, even though antidepressants were perhaps excessively used until the recent concern over their increasing suicide risk.  So it is a very good strategy to extend patent somewhat by cornering the adolescent...

Agomelatine (Valdoxan; Servier with rights in Europe and Novartis in the US) is a mixed melatonin (MT1 and MT2) agonist and serotonin 5-HT2c antagonist in development as a treatment for major depression and generalized anxiety disorder.  Its melatonergic properties make it unique among antidepressant...

This makes it easier for me to avoid mention or suggestion to my patients to try glitazones. I am having an easier time now with prior approvals of Januvia after only a trial of Metformin and sulfonylureas

We have been hoping that remonibant, the cannabinoid antagonist, would allow patients with obesity to lose weight "pharmacologically" without actually having to undergo the significant effort to reverse a lifetime of self-destructive behaviors that have culminated in pathological obesity--obesity that...